ND Committee Review
Internal Medical Policy Committee 1-14-2019
Adopted
policy
Internal Medical Policy Committee 11-14-2019 Code update
Internal Medical Policy Committee 7-22-2020 Change J9229 to pre-certification drug
Internal Medical Policy Committee 11-19-2020
Added
NCCN recommendations
Internal Medical Policy Committee 11-23-2021 Annual review, no clinical content change
Internal Medical Policy Committee 11-29-2022
Effective January 1, 2023
- Removed
NCCN recommendations;
and
- Added
this statement 'Inotuzumab ozogamicin (Besponsa) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.';
and
- Updated
experimental/investigational statement
Internal Medical Policy Committee 11-15-2023 Annual review, no clinical content change
Internal Medical Policy Committee 11-19-2024
Effective December 08, 2024